Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis

December 12th 2022

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

Crovalimab Achieves Stable Hemolysis Control, Transfusion Avoidance in Paroxysmal Nocturnal Hemoglobinuria

December 11th 2022

Crovalimab led to rapid and stable hemolysis control and transfusion avoidance, with no new safety signals, in Chinese patients with paroxysmal nocturnal hemoglobinuria.

Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML

December 10th 2022

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

Neoadjuvant Cemiplimab/REGN3767 Plus Paclitaxel Improves pCR in Early-stage, High-risk HER2– Breast Cancer

December 9th 2022

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022

December 8th 2022

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis

November 30th 2022

The combination of NT-I7 and pembrolizumab showed significant clinical activity in checkpoint inhibitor–naïve, relapsed/refractory microsatellite stable colorectal cancer and pancreatic cancer without liver metastasis.

PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer

November 23rd 2022

PDS0101 given in conjunction with chemoradiation elicited an 100% overall response rate, along with tumor shrinkage greater than 60%, in 9 patients with high-risk, locally advanced cervical cancer, according to results of the phase 2 IMMUNOCERV trial.

Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma

November 16th 2022

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13th 2022

CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.

CTX130 Allogeneic CAR T-cell Therapy Shows Tolerability, Intriguing Activity in Advanced RCC

November 11th 2022

CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.

Pembrolizumab/Eftilagimod alpha Combo Shows Durable Responses in Frontline NSCLC

November 11th 2022

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors

November 10th 2022

A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.

FDA Approves Durvalumab/Tremelimumab in Unresectable HCC

October 24th 2022

The FDA has approved durvalumab (Imfinzi) in combination with tremelimumab (Imjudo) for the treatment of adult patients with unresectable hepatocellular carcinoma.

Patients With Bone Sarcomas of Lower-Extremity and Non-Private Insurance Linked With Higher Amputation Rates, Worse Outcomes

September 5th 2022

Amputation is an independent predictor of poor outcomes among patients with high-grade bone sarcoma of lower extremity, and non-private insurance was found to be linked with increased likelihood of amputation and an advanced stage at presentation in this patient population.

Orca-T Continues to Break New Ground in Hematologic Cancers

June 9th 2022

Samer Srour, MD, discusses his experiences with the Orca-T and Orca-Q programs, and highlights how this type of treatment is shifting the field of hematologic malignancies.

Enzalutamide/ADT Shows Long-Term Survival Benefit in mHSPC Regardless of Prior Local Treatment

May 14th 2022

Enzalutamide added to androgen deprivation therapy demonstrated a benefit in overall survival, radiographic progression-free survival, undetectable prostate-specific antigen rates, objective response rates, and other end points vs placebo/ADT in patients with metastatic hormone-sensitive prostate cancer regardless of whether or not they received prior local therapy.

Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer

May 7th 2022

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

Addition of Apalutamide to ADT Does Not Reduce HRQOL in Metastatic Castration-Sensitive Prostate Cancer

May 3rd 2022

The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

Addition of Ublituximab/Umbralisib to Ibrutinib Produces High uMRD Rate in CLL

May 2nd 2022

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)